Hck Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP 2 is distinguished by its unique reactivity as an acid halide, exhibiting a propensity for nucleophilic acyl substitution reactions. Its electronic structure promotes strong electrophilic character, enabling rapid interactions with a variety of nucleophiles. The compound's steric configuration influences reaction kinetics, leading to selective pathways. Furthermore, PP 2 demonstrates intriguing solvation dynamics, which can modulate its reactivity in different solvent environments, enhancing its versatility in synthetic applications. | ||||||
PP121 | 1092788-83-4 | sc-301605 | 5 mg | $139.00 | 1 | |
PP121 is characterized by its exceptional electrophilic nature as an acid halide, facilitating swift nucleophilic attacks. Its unique steric arrangement allows for selective reactivity, influencing the formation of specific products. The compound exhibits notable stability in various solvent systems, which can significantly alter its reactivity profile. Additionally, PP121's interaction with nucleophiles is governed by distinct kinetic parameters, making it a compelling subject for mechanistic studies in organic synthesis. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Targets BCR-ABL kinase, inhibiting tyrosine kinase activity and blocking cell proliferation, studied in the research of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Inhibits multiple kinases, including RAF and VEGFR, disrupting signaling pathways in cancer cells. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Targets EGFR tyrosine kinase, preventing cell division and growth, prescribed for non-small cell lung cancer and pancreatic cancer therapy. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $412.00 | 32 | |
Dual inhibitor of EGFR and HER2 kinases, hindering receptor activation and signaling in HER2-positive breast cancer. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Blocks multiple kinases including BCR-ABL, Src, and c-KIT, used for CML and acute lymphoblastic leukemia (ALL). | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $115.00 $415.00 | 11 | |
Targets mutated BRAF kinase, inhibiting the MAPK pathway, approved for melanoma with BRAF V600E mutation. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Inhibits CDK4/6 kinases, preventing cell cycle progression, prescribed for hormone receptor-positive breast cancer. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Targets EGFR tyrosine kinase, blocking cell growth signaling, used for non-small cell lung cancer research. | ||||||